Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Advances in molecular biology enable targeted therapies and precision medicine.
• Targeted therapies improve patient treatment but pose challenges in patient selection and response assessment.
• Developing treatments for rare molecular subtypes presents unique difficulties.

Purpose of the Study:

• To provide additional information on developing targeted therapies for diseases with low-frequency molecular subsets.
• To address challenges in identifying patient populations and assessing treatment response for rare molecular subtypes.
• To supplement the US Food and Drug Administration's draft guidance on targeted therapy development.

Main Methods:

• Review of challenges in targeted therapy development for rare molecular subtypes.
• Analysis of strategies for patient subset identification and response assessment.
• Discussion of diagnostic test development for patient stratification.

Main Results:

• Identified key challenges in developing targeted therapies for low-frequency molecular subsets.
• Highlighted the importance of diagnostic tests for patient identification.
• Emphasized the need for robust benefit-risk assessment in rare disease contexts.

Conclusions:

• Developing targeted therapies for rare molecular subtypes requires specific strategies.
• Precision medicine approaches must overcome challenges in patient stratification and response heterogeneity.
• Regulatory guidance is crucial for advancing treatment development in rare molecular diseases.